Immunoproteasome as a therapeutic target in obesity-related brain inflammation and metabolic disorders
- PMID: 40145949
- PMCID: PMC12407525
- DOI: 10.4103/NRR.NRR-D-24-01358
Immunoproteasome as a therapeutic target in obesity-related brain inflammation and metabolic disorders
Figures
References
-
- Albornoz N, Álvarez-Indo J, de la Peña A, Arias-Muñoz E, Coca A, Segovia-Miranda F, Kerr B, Budini M, Criollo A, García-Robles MA, Morselli E, Soza A, Burgos PV. Targeting the immunoproteasome in hypothalamic neurons as a novel therapeutic strategy for high-fat diet-induced obesity and metabolic dysregulation. J Neuroinflammation. 2024;21:191. - PMC - PubMed
-
- Bhattarai D, Lee MJ, Baek A, Yeo IJ, Miller Z, Baek YM, Lee S, Kim DE, Hong JT, Kim KB. LMP2 inhibitors as a potential treatment for Alzheimer’s disease. J Med Chem. 2020;63:3763–3783. - PubMed
-
- Ding Q, Martin S, Dimayuga E, Bruce-Keller AJ, Keller JN. LMP2 knock-out mice have reduced proteasome activities and increased levels of oxidatively damaged proteins. Antioxid Redox Signal. 2006;8:130–135. - PubMed
-
- Guo T, Liu C, Yang C, Wu J, Su P, Chen J. Immunoproteasome subunit PSMB8 regulates microglia-mediated neuroinflammation upon manganese exposure by PERK signaling. Food Chem Toxicol. 2022;163:112951. - PubMed
LinkOut - more resources
Full Text Sources